Ultragenyx Pharmaceutical | RARE - Market Capitalization


Ultragenyx Pharmaceutical reported $2.53B in Market Capitalization this June of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.8B 724M Mar/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
BioCryst Pharmaceuticals USD 1.66B 64M Dec/2025
BioMarin Pharmaceutical USD 10.86B 553M Mar/2026
Esperion Therapeutics USD 885M 351M Dec/2025
Immunic USD 64M 23M Dec/2025
Insmed USD 35.3B 1.82B Mar/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
Karyopharm Therapeutics USD 1.05B 912M Jun/2026
Kyowa Hakko Kirin JPY 1.36T 26.81B Mar/2026
Moderna USD 20.15B 8.53B Mar/2026
Neurocrine Biosciences USD 13.25B 890M Mar/2026
PTC Therapeutics USD 5.64B 460M Mar/2026
Regeneron Pharmaceuticals USD 81.68B 560M Mar/2026
Sarepta Therapeutics USD 2.28B 30M Mar/2026
Ultragenyx Pharmaceutical USD 2.06B 159M Mar/2026
Vertex Pharmaceuticals USD 113.58B 1.44B Mar/2026